• Dailong Li, Sha Wan, Wanqiang Li, Chunlai Cheng, Lu Xu, and Peng Gu.
• Department of Oncology, General Hospital of The Yangtze River Shipping, Wuhan, Hubei, China.
• Medicine (Baltimore). 2023 Sep 8; 102 (36): e34983e34983.

BackgroundTo assess the safety and efficacy of sorafenib and sunitinib as first-line treatments for metastatic renal cell carcinoma (mRCC), to provide evidence-based support for clinical decision-making regarding rational drug use.MethodsUntil May 10, 2023, a comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang databases to identify clinical studies comparing sorafenib with sunitinib as first-line treatment for mRCC. The literature was screened, data extracted, and quality evaluated independently by 2 researchers. Meta-analysis was conducted using Revman5.4 software.ResultsA total of 3741 patients were enrolled in 20 studies. The meta-analysis results indicated that there were no significant differences in the 2- and 5-year progression-free survival (PFS) and overall survival (OS) rates between the sorafenib and sunitinib groups (P > .05). The disease control rate (DCR) was comparable between the 2 groups (P > .05), while the objective response rate (ORR) was higher in the sunitinib group (P = .03). However, subgroup analysis revealed no significant differences in ORR, DCR, 2- and 5-year PFS, and OS rates between sorafenib and sunitinib among both Asian populations as well as European and American populations (P > .05). In terms of drug-related adverse events, the incidence of grade ≥ 3 hypertension, leukopenia, neutropenia, thrombocytopenia, anemia, nausea and vomiting were significantly lower in the sorafenib group compared to the sunitinib group (P < .05).ConclusionIn the first-line treatment of mRCC, sorafenib exhibits comparable efficacy to sunitinib but with lower toxicity.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…